White Rose Research Online

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk
Universities of Leeds, Sheffield and York

Deposited via The University of Leeds.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/138254/

Version: Accepted Version

Article:
Dubash, S, Marianayagam, T, Tinazzi, I et al. (2018) Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, Key 26. ISSN: 1462-0324

https://doi.org/10.1093/rheumatology/key267

Copyright © 2018, Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record, Dubash, S, Marianayagam, T, Tinazzi, I et al. (12 more authors) (2018) Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, Key 26 is available online at: https://doi.org/10.1093/rheumatology/key267

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

UNIVERSITY OF LEEDS
University of Sheffield
UNIVERSITY of York

Patient number	1	2	3	4	5	6	7	8	9	10	11
Age, M/F	28, M	48, M	33, F	50, M	35, F	40, F	21, F	52, M	45, F	44, F	72, M
Hospitalised	Y	N	N	N	Y	Y	N	N	Y	N	N
Vedolizumab exposure (weeks)	14	20	20	6	8	10	5	12	4	52	20
Pre-existing SpA	Y	N	N	N	N	N	N	N	Y	N	N
axSpA perSpA Osteitis or Enthesitis	Y Y +++	Y Y ++	Y N ++	Y N +++	Y N NA	N Y ++	Y Y ++	N Y +++	Y Y +++	Y Y +++	N Y +++
MRI/USS (imaging feature)	MRI: Extreme Perifacetal spinal vertebral oedema	MRI: Bilateral sacroiliitis	MRI: Bilateral sacroiliitis	MRI: Extensive severe thoraco-lumbar vertebral oedema/ osteitis and IRLs	MRI –ve, nr-axSpA	MRI: Enthesitis/periostitis distal tibio-fibular	MRI: Right sided sacroiliitis (also XR +ve, fulfilling mNY criteria)	USS: Marked Achilles enthesitis PD +ve	MRI: Bilateral sacroiliitis	MRI: Bilateral sacroiliitis USS: Knee synovitis, hand flexor tenosynovitis, PD +ve	USS: elbow, knee and wrist synovitis, common extensor enthesitis.
HLA-B27	N	NA	NA	N	Y	NA	N	N	N	N	NA
Smoker (cpd)	15	NA	NA	25	N	N	N	N	N	N	N
EAMs (Uveitis, PsO)	N	N	PsO	N	PsO	N	N	N	PsO	N	PsO
IBD type/ activity	CD/ Low/ controlled	IC/ Low/ controlled	CD/NA	CD/ Active (high)	UC/ Low/ controlled	UC/ Low/ controlled	IC/ Low/ controlled	CD/ Active (moderate)	UC/ Low/ controlled	CD/Active (high)	UC/ Low/ controlled
CRP at flare (mg/l)	216	<5	<5	24	24	28	55	68	33	80	88
Concomitant DMARD	MTX 15mg o.w	AZA 150mg o.d	Pred 0.5mg o.d	None	None	Pred 4mg o.d	None	None	MTX 7.5mg o.w	None	Pred 15mg o.d
TNFi failure	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N
Previous TNFi /DMARDs	IFX ADA CZP	ADA IFX	AZA IFX ADA	IFX ADA	MSZ CYSP IFX ADA	6-MP AZA ADA	IFX	6-MP, AZA	IFX Secukinumab ADA	IFX CZP GLM	None
Vedolizumab discontinued	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y
Treatment change	GLM	Patient declined treatment for SpA.	Bilateral sacroiliac joint injection and switched to UST	CZP	CZP: intolerance. SZP: intolerance. Switched to GLM.	TOFA+ ZOL	ADA	ADA+Pred	VDZ +Pred 10mg o.d + Apremilast; developed significant depression. Apremilast switched back	ETN+ VDZ	ADA

									to MTX 7.5mg o.w.		
Outcome	Moderate IBD and SpA activity at 6 months, CRP 58 BASDAI 6.9 (previous 8.8)	IBD in remission at 6 months (colonoscopy normal) SpA outcomes: NA	NA	IBD: controlled SpA: mild to moderate activity at 6 months, CRP 19	IBD in remission. SpA activity is moderate at 6 months.	Periostitis and enthesitis resolved at 6 months.	Mild axSpA. Skin and perSpA in remission at 1 month.	Achilles enthesitis much improved. Moderate CD activity at 1 month	IBD/ SpA /Skin PsO all well controlled at 6 months.	IBD and SpA in drug controlled remission at 6 months.	NA

Y: yes; N: no; NA: not available; cpd: cigarettes per day; EAMs :extra-articular manifestations; nr: non-radiographic; Osteitis or Enthesitis: + mild, ++ moderate, +++ severe; o.d: once daily; o.w: once weekly; CD: Crohn's disease; UC: ulcerative colitis; IC: intermediate colitis; IRLs: inflammatory Romanus corner lesions; PD: Power Doppler; XR: X-ray; TNFi: tumour necrosis factor inhibitor; ADA: adalimumab; CZP: certolizumab pegol; CYSP: cyclosporine; GLM: golimumab; IFX: infliximab; MSZ: mesalazine; MTX: methotrexate; Pred :prednisolone; TOFA: tofacitinib; UST: ustekinumab; VDZ: vedolizumab; ZOL: zolendronate.

A




B



C



D



E

